Real-world evidence of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Scheme in patients with relapsed / refractory multiple myeloma

Carfilzomib, lenalidomide and dexamethasone (KRd) is still a widely used treatment option for patients with relapsed / refractory multiple myeloma (RRMM). However, there is limited real-world evidence. Here we evaluated the efficacy and safety of KRd in patients with RRMM treated following the standard clinical practice of the hospitals in the Catalan region. This was a retrospective, observational study. The objective response rate (ORR) according to IMWG criteria was the primary endpoint. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). The study planned to include at least 100-150 patients. In total 194 patients were included. Median age was 64 years (range: 40-88) and 56% were male. All patients had received bortezomib. Additionally, 89 patients (46%) had received thalidomide and 29 (15%) lenalidomide. The ORR was 73% (95% CI: 66-79), with 72 patients (37%) having ≥ CR. The ORR was influenced by ISS score, number of previous treatments and exposure to lenalidomide. The median PFS was 26 months and 2-years OS rate 70%. The ISS stage and LDH levels were independent prognostic factors of survival. In conclusion, the KRd scheme led to a good effectiveness comparable safety profile to the phase III clinical trial in patients with RRMM.

Authors

Institutions

Publication Details

Journal
Annals of Hematology
Published
2025-02-01
DOI
https://doi.org/10.1007/s00277-025-06240-1
Citations
3
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
5.31
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real-world evidence of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Scheme in patients with relapsed / refractory multiple myeloma

Alicia Senín, Mercedes Gironella, Randa Ben Azaiz, Josep Sarrà et al.
3 citations
Annals of Hematology
Multiple Myeloma Research and Treatments
5.31
article

Real-world evidence of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Scheme in patients with relapsed / refractory multiple myeloma

Alicia Senín, Mercedes Gironella, Randa Ben Azaiz, Josep Sarrà, Maria-Elena Cabezudo, Yolanda Campos, Carlos Fernández de Larrea, Marta Santaliestra, Juan Alfons Soler, Cristina Motlló, Antoni García‐Guiñón, María José Jimenez, Paola Charry, Esther Sancho, Marta García‐Pintos, Miquel Granell, Josep‐Maria Martí‐Tutusaus, Eugènia Abella, Yasmina Seres, Izarbe Delgado, María José Herranz, Laura Segura de la Torre
article en
3 citations

Abstract

Carfilzomib, lenalidomide and dexamethasone (KRd) is still a widely used treatment option for patients with relapsed / refractory multiple myeloma (RRMM). However, there is limited real-world evidence. Here we evaluated the efficacy and safety of KRd in patients with RRMM treated following the standard clinical practice of the hospitals in the Catalan region. This was a retrospective, observational study. The objective response rate (ORR) according to IMWG criteria was the primary endpoint. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). The study planned to include at least 100-150 patients. In total 194 patients were included. Median age was 64 years (range: 40-88) and 56% were male. All patients had received bortezomib. Additionally, 89 patients (46%) had received thalidomide and 29 (15%) lenalidomide. The ORR was 73% (95% CI: 66-79), with 72 patients (37%) having ≥ CR. The ORR was influenced by ISS score, number of previous treatments and exposure to lenalidomide. The median PFS was 26 months and 2-years OS rate 70%. The ISS stage and LDH levels were independent prognostic factors of survival. In conclusion, the KRd scheme led to a good effectiveness comparable safety profile to the phase III clinical trial in patients with RRMM.

Annals of HematologyVol. 104(2)
Hospital de Sant Pau (ES), Hospital Universitari Arnau de Vilanova (ES), Althaia (ES), Consorci Sanitari de Terrassa (ES), Hospital General de Granollers (ES), Hospital Clínic de Barcelona (ES), Hospital Sant Pau i Santa Tecla (ES), Hospital de Sabadell (ES), Vall d'Hebron Hospital Universitari (ES), Mútua Terrassa (ES), Hospital Del Mar (ES), Hospital de Sant Joan Despí Moisès Broggi (ES), Hospital Universitari Joan XXIII de Tarragona (ES), Hospital Universitari Germans Trias i Pujol (ES), Hospital Universitari de Girona Doctor Josep Trueta (ES), Universitat de Barcelona (ES)
Zero hunger
Openalex Percentile: Top 6%
Multiple Myeloma Research and Treatments
5.31
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.